Pemphigus vulgaris

Summary

Pemphigus vulgaris (MONDO:0008219) is a disease with 2 cohort genes (11 GWAS associations across 4 studies) and 39 clinical trials. Top therapeutic interventions include efgartigimod alfa, mycophenolate mofetil, and azathioprine.

At a glance

• Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
• Cohort genes: 2
• GWAS associations: 11
• Phenotypes (HPO): 20
• Clinical trials: 39

Clinical features

Epidemiology

Prevalence records

8 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-5 / 10 000	18	Europe	Validated
Annual incidence	1-9 / 1 000 000	0.13	France	Validated
Annual incidence	1-9 / 1 000 000	0.7	United Kingdom	Validated
Annual incidence	<1 / 1 000 000	0.076	Finland	Validated
Annual incidence	1-9 / 1 000 000	0.47	Bulgaria	Validated
Annual incidence	1-9 / 1 000 000	0.42	United States	Validated
Annual incidence	1-9 / 1 000 000	0.25	Tunisia	Validated
Point prevalence	1-9 / 100 000	9.482	Germany	Validated

Signs & symptoms

Clinical features (HPO)

20 HPO clinical features (Orphanet curated; top 20 by frequency):

HPO ID	Term	Frequency
HP:0000987	Atypical scarring of skin	Very frequent (80-99%)
HP:0001025	Urticaria	Very frequent (80-99%)
HP:0001824	Weight loss	Very frequent (80-99%)
HP:0002719	Recurrent infections	Very frequent (80-99%)
HP:0002960	Autoimmunity	Very frequent (80-99%)
HP:0008872	Feeding difficulties in infancy	Very frequent (80-99%)
HP:0031446	Erosion of oral mucosa	Very frequent (80-99%)
HP:0100792	Acantholysis	Very frequent (80-99%)
HP:0100838	Recurrent cutaneous abscess formation	Very frequent (80-99%)
HP:0200097	Oral mucosal blisters	Very frequent (80-99%)
HP:0000716	Depression	Frequent (30-79%)
HP:0000739	Anxiety	Frequent (30-79%)
HP:0008066	Abnormal blistering of the skin	Frequent (30-79%)
HP:0011968	Feeding difficulties	Frequent (30-79%)
HP:0034194	Suprabasal cleavage	Frequent (30-79%)
HP:4000013	Anti-desmoglein-1 antibody positivity	Frequent (30-79%)
HP:4000014	Anti-desmoglein-3 antibody positivity	Frequent (30-79%)
HP:0002293	Alopecia of scalp	Occasional (5-29%)
HP:0012531	Pain	Occasional (5-29%)
HP:0030351	Urticarial plaque	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	pemphigus vulgaris
Mondo ID	MONDO:0008219
EFO	EFO:0004719
MeSH	C536645
OMIM	169610
Orphanet	704
DOID	DOID:0060851
ICD-10-CM	L10.0
ICD-11	278358681
NCIT	C34910
SNOMED CT	49420001
UMLS	C0030809
MedGen	10621
GARD	0007355
MedDRA	10052802
Is cancer (heuristic)	no

Data availability: 11 GWAS associations (4 studies) · 18 cell lines.

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › autoimmune bullous skin disease › pemphigus › pemphigus vulgaris

Related subtypes (5): pemphigoid gestationis, Hailey-Hailey disease, herpetiform pemphigus, pemphigus erythematosus, pemphigus foliaceus

Subtypes (1): pemphigus vegetans

Genetics & variants

GWAS landscape

11 GWAS associations across 4 studies. Top hits map to 3 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs70993900	1e-45	HLA-DRB1 - HLA-DQA1	?	18.57
HLA-DRB1*14:04	2e-38		?	6.28
rs28483633	3e-35	HLA-DQA1 - HLA-DQB1	?	5.86
rs9469220	4e-19	HLA-DQB1 - MTCO3P1	G	3.36
rs7454108	3e-12	MTCO3P1 - HLA-DQB3	?	3.25
rs11218708	3e-08	RNU6-592P - GLULP3	A	1.54
rs1074532	1e-06	EPHA5-AS1 - RNU2-40P	A	1.81
rs117814792	2e-06	LINC02161 - MIR3660	A	3.12
rs1051336	3e-06	HLA-DRA	?	3.03
rs9262122	5e-06	PPP1R10	?	2.73
rs16837853	8e-06	THSD7B	G	2

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST008068	Zhang S	2018	255	0	Subtype-Specific Inherited Predisposition to Pemphigus in Chinese Population.
GCST006584	Gao J	2018	240	1,031	Association study and fine-mapping major histocompatibility complex analysis of pemphigus vulgaris in a Han Chinese population.
GCST006521	Sun Y	2018	101	0	Investigation of the Predisposing Factor of Pemphigus and its clinical subtype through a Genome-wide association and next generation sequence analysis.
GCST001452	Sarig O	2012	100	0	Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	1
Tier 3: regulatory	2
Tier 4: intronic/intergenic	8

MAF distribution

Bucket	Variants
common (>=0.05)	9
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	2

Functional consequences

Consequence	Count
intergenic_variant	4
intron_variant	3
unknown	1
TF_binding_site_variant	1
regulatory_region_variant	1
3_prime_UTR_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs70993900	6	32618381	AC>A,ACC	0.09	intergenic_variant	HLA-DRB1 - HLA-DQA1	1e-45	Tier 4: intronic/intergenic
HLA-DRB1*14:04							2e-38	Tier 4: intronic/intergenic
rs28483633	6	32657097	C>A	0.05	TF_binding_site_variant	HLA-DQA1 - HLA-DQB1	3e-35	Tier 3: regulatory
rs9469220	6	32690533	G>A,T	0.33	intergenic_variant	HLA-DQB1 - MTCO3P1	4e-19	Tier 4: intronic/intergenic
rs7454108	6	32713706	T>C	0.05	intergenic_variant	MTCO3P1 - HLA-DQB3	3e-12	Tier 4: intronic/intergenic
rs11218708	11	122601355	G>A	0.21	regulatory_region_variant	RNU6-592P - GLULP3	3e-08	Tier 3: regulatory
rs1074532	4	65791342	A>C,G	0.05	intergenic_variant	EPHA5-AS1 - RNU2-40P	1e-06	Tier 4: intronic/intergenic
rs117814792	5	90014044	G>A		intron_variant	LINC02161 - MIR3660	2e-06	Tier 4: intronic/intergenic
rs1051336	6	32444815	G>A,C	0.05	3_prime_UTR_variant	HLA-DRA	3e-06	Tier 2: splice/UTR
rs9262122	6	30606065	T>C	0.05	intron_variant	PPP1R10	5e-06	Tier 4: intronic/intergenic
rs16837853	2	137014290	A>C,G	0.05	intron_variant	THSD7B	8e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 14 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
HLA-DRB1	Orphanet:2073	Narcolepsy type 1
HLA-DRB1	Orphanet:220393	Diffuse cutaneous systemic sclerosis
HLA-DRB1	Orphanet:220402	Limited cutaneous systemic sclerosis
HLA-DRB1	Orphanet:220407	Limited systemic sclerosis
HLA-DRB1	Orphanet:3437	Vogt-Koyanagi-Harada disease
HLA-DRB1	Orphanet:397	Giant cell arteritis
HLA-DRB1	Orphanet:477738	Pediatric multiple sclerosis
HLA-DRB1	Orphanet:536	Systemic lupus erythematosus
HLA-DRB1	Orphanet:545	Follicular lymphoma
HLA-DRB1	Orphanet:703	Bullous pemphigoid
HLA-DRB1	Orphanet:747	Autoimmune pulmonary alveolar proteinosis
HLA-DRB1	Orphanet:797	Sarcoidosis
HLA-DRB1	Orphanet:83465	Narcolepsy type 2
HLA-DRB1	Orphanet:85414	Systemic-onset juvenile idiopathic arthritis

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
UBASH3B	HGNC:29884	ENSG00000154127	Q8TF42	Ubiquitin-associated and SH3 domain-containing protein B	gwas
HLA-DRB1	HGNC:4948	ENSG00000196126	P01911	HLA class II histocompatibility antigen, DRB1 beta chain	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
UBASH3B	Ubiquitin-associated and SH3 domain-containing protein B	Interferes with CBL-mediated down-regulation and degradation of receptor-type tyrosine kinases.
HLA-DRB1	HLA class II histocompatibility antigen, DRB1 beta chain	A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Phosphatase	1	42.0×	0.047
Antibody/Immunoglobulin	1	14.6×	0.067

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
UBASH3B	Phosphatase	yes		SH3_domain, UBA-like_sf, His_Pase_superF_clade-1
HLA-DRB1	Antibody/Immunoglobulin	yes		MHC_II_b_N, Ig/MHC_CS, Ig_C1-set

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
cerebellar cortex	1
cerebellum	1
pons	1
granulocyte	1
right lung	1
vermiform appendix	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
UBASH3B	212	ubiquitous	marker	pons, cerebellum, cerebellar cortex
HLA-DRB1	131	tissue_specific	marker	vermiform appendix, granulocyte, right lung

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
HLA-DRB1	3,448
UBASH3B	1,820

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
HLA-DRB1	P01911	108
UBASH3B	Q8TF42	6

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 7. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Translocation of ZAP-70 to Immunological synapse	1	634.4×	0.004	HLA-DRB1
Phosphorylation of CD3 and TCR zeta chains	1	543.8×	0.004	HLA-DRB1
Co-inhibition by PD-1	1	519.1×	0.004	HLA-DRB1
Generation of second messenger molecules	1	346.1×	0.005	HLA-DRB1
Downstream TCR signaling	1	128.3×	0.009	HLA-DRB1
Interferon gamma signaling	1	125.5×	0.009	HLA-DRB1
MHC class II antigen presentation	1	89.2×	0.011	HLA-DRB1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of interleukin-4 production	1	8426.0×	0.003	HLA-DRB1
antigen processing and presentation of endogenous peptide antigen via MHC class II	1	4213.0×	0.003	HLA-DRB1
regulation of interleukin-10 production	1	4213.0×	0.003	HLA-DRB1
myeloid dendritic cell antigen processing and presentation	1	2808.7×	0.003	HLA-DRB1
regulation of T-helper cell differentiation	1	2106.5×	0.003	HLA-DRB1
positive regulation of CD4-positive, alpha-beta T cell activation	1	2106.5×	0.003	HLA-DRB1
positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation	1	1685.2×	0.003	HLA-DRB1
positive regulation of T cell mediated immune response to tumor cell	1	1203.7×	0.004	HLA-DRB1
T-helper 1 type immune response	1	936.2×	0.004	HLA-DRB1
positive regulation of memory T cell differentiation	1	936.2×	0.004	HLA-DRB1
positive regulation of monocyte differentiation	1	766.0×	0.004	HLA-DRB1
regulation of osteoclast differentiation	1	766.0×	0.004	UBASH3B
detection of bacterium	1	702.2×	0.004	HLA-DRB1
negative regulation of platelet aggregation	1	702.2×	0.004	UBASH3B
collagen-activated tyrosine kinase receptor signaling pathway	1	648.1×	0.004	UBASH3B
peptide antigen assembly with MHC class II protein complex	1	526.6×	0.004	HLA-DRB1
negative regulation of bone resorption	1	495.6×	0.004	UBASH3B
inflammatory response to antigenic stimulus	1	468.1×	0.004	HLA-DRB1
regulation of release of sequestered calcium ion into cytosol	1	468.1×	0.004	UBASH3B
protein tetramerization	1	312.1×	0.006	HLA-DRB1
negative regulation of inflammatory response to antigenic stimulus	1	300.9×	0.006	HLA-DRB1
antigen processing and presentation of exogenous peptide antigen via MHC class II	1	271.8×	0.006	HLA-DRB1
negative regulation of osteoclast differentiation	1	271.8×	0.006	UBASH3B
positive regulation of T cell mediated cytotoxicity	1	255.3×	0.006	HLA-DRB1
positive regulation of immune response	1	240.7×	0.006	HLA-DRB1
macrophage differentiation	1	234.1×	0.006	HLA-DRB1
positive regulation of T cell activation	1	221.7×	0.006	HLA-DRB1
negative regulation of type II interferon production	1	191.5×	0.007	HLA-DRB1
negative regulation of signal transduction	1	187.2×	0.007	UBASH3B
positive regulation of insulin secretion involved in cellular response to glucose stimulus	1	187.2×	0.007	HLA-DRB1

Therapeutics

Drugs indicated for this disease

3 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dexamethasone	Approved (phase 4)
Prednisone	Approved (phase 4)
Rituximab	Approved (phase 4)
Mycophenolate Mofetil	Phase 3 (in late-stage trials)
Ofatumumab	Phase 3 (in late-stage trials)
Rilzabrutinib	Phase 3 (in late-stage trials)
Triamcinolone Acetonide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Azathioprine, Dapsone, Etanercept, Human Immunoglobulin G, Ianalumab, Parsaclisib.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
UBASH3B	1	3
HLA-DRB1	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
REBAMIPIDE	3	UBASH3B

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
HLA-DRB1	17	Binding:17
UBASH3B	10	Binding:10

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
REBAMIPIDE	3	UBASH3B

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	UBASH3B
C	Druggable family + PDB, no drug	1	HLA-DRB1
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
HLA-DRB1	17	—

Clinical trials & evidence

Clinical trials

Clinical trials: 39.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	13
Not specified	12
PHASE3	6
PHASE1/PHASE2	3
PHASE1	3
PHASE4	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05303272	PHASE4	UNKNOWN	A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
NCT06846255	PHASE4	COMPLETED	Comparing DCP and DAP for Pemphigus Vulgaris
NCT00683930	PHASE3	COMPLETED	A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
NCT01920477	PHASE3	TERMINATED	Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
NCT02383589	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
NCT04598451	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
NCT04598477	PHASE3	TERMINATED	A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
NCT05594472	PHASE3	UNKNOWN	Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
NCT04422912	PHASE1/PHASE2	RECRUITING	A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
NCT06663943	PHASE1/PHASE2	NOT_YET_RECRUITING	A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
NCT00135720	PHASE2	COMPLETED	Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris
NCT00429533	PHASE2	TERMINATED	Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
NCT00483119	PHASE2	TERMINATED	Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
NCT00606749	PHASE2	COMPLETED	Use of KC706 for the Treatment of Pemphigus Vulgaris
NCT00626678	PHASE2	COMPLETED	Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
NCT01930175	PHASE2	TERMINATED	Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris
NCT02704429	PHASE2	COMPLETED	A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
NCT03075904	PHASE1/PHASE2	TERMINATED	A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
NCT03334058	PHASE2	COMPLETED	A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus
NCT03780166	PHASE2	WITHDRAWN	A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
NCT04023149	PHASE2	UNKNOWN	Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris
NCT04540133	PHASE2	COMPLETED	Dexamethasone Solution and Dexamethasone in Mucolox™
NCT05000216	PHASE2	TERMINATED	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT07461103	PHASE2	COMPLETED	Effect of Topical Insulin on Healing Rate of Pemphigus Lesions
NCT06581562	PHASE1	RECRUITING	Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
NCT00063752	PHASE1	COMPLETED	Safety Study of PI-0824 to Treat Pemphigus Vulgaris
NCT03239470	PHASE1	TERMINATED	Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
NCT02753777	Not specified	RECRUITING	Autoimmune Blistering Diseases Study
NCT05635266	Not specified	RECRUITING	Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT06863454	Not specified	NOT_YET_RECRUITING	Trichoscopy as a Monitoring Tool for Activity and Remission in Pemphigus Vulgaris: A Clinical Study Supported by Immunological Evaluation.
NCT06971172	Not specified	NOT_YET_RECRUITING	Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.
NCT07384221	Not specified	RECRUITING	Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients
NCT03177213	Not specified	UNKNOWN	Serum IL-21 Levels in Patients With Pemphigus Vulgaris
NCT04096222	Not specified	UNKNOWN	Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
NCT04117529	Not specified	UNKNOWN	Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus
NCT05338112	Not specified	UNKNOWN	Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
NCT06167408	Not specified	COMPLETED	Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
NCT06654817	Not specified	COMPLETED	Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
NCT07428915	Not specified	COMPLETED	Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EFGARTIGIMOD ALFA	4	3
MYCOPHENOLATE MOFETIL	4	2
AZATHIOPRINE	4	1
DAPSONE	4	1
ELASOMERAN	4	1
GENTAMICIN SULFATE	4	1
OFATUMUMAB	4	1
TOZINAMERAN	4	1
IANALUMAB	3	1
PARSACLISIB	3	1
RILZABRUTINIB	3	1
AB-101	2	1
ITX-5061	2	1
LUMROTATUG	2	1
ORILANOLIMAB	2	1
PI-0824	1	1